Oculis Sets Stage for Key Data Readouts in 2026 with Investor Conferences

Event summary

  • Oculis to present at Needham Healthcare Conference (April 14) and Van Lanschot Kempen Life Sciences Conference (April 15-16).
  • Key pipeline updates include OCS-01 DME topline results expected in June 2026 and Licaminlimab DED results planned for late 2026.
  • Privosegtor granted FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis.
  • Company targeting 6 pivotal readouts with current funding.

The big picture

Oculis is positioning itself as a leader in neuro-ophthalmology with a string of upcoming data readouts. The company's focus on precision medicine and its strong regulatory momentum with Privosegtor could reshape treatment paradigms in optic neuropathies. With a potential $7B+ U.S. market opportunity, Oculis' ability to execute on its pipeline will be critical to watch.

What we're watching

Clinical Execution
Whether Oculis can deliver on its ambitious 6-pivotal-readout plan with current funding.
Regulatory Momentum
The pace at which Privosegtor advances through optic neuropathy indications with its dual Breakthrough/PRIME designations.
Market Opportunity
How Oculis positions its precision medicine approach in dry eye disease against existing treatments.